skip navigation nih record
Vol. LXIII, No. 22
October 28, 2011

previous story

next story

McIntosh To Give Inaugural NIAID Chanock Lecture, Nov. 4

Dr. Kenneth McIntosh
Dr. Kenneth McIntosh, professor of pediatrics at Harvard Medical School and the Harvard School of Public Health and senior physician in medicine at Children’s Hospital Boston, will deliver the inaugural Robert M. Chanock Memorial Lecture. His talk, “Human Coronaviruses: The Whole Story,” will be held on Friday, Nov. 4, at 10 a.m. in the first floor conference room of Bldg. 50.

Starting in 1965, McIntosh worked under Chanock in the NIAID Laboratory of Infectious Diseases (LID), where he isolated, characterized and performed epidemiological studies with a group of coronaviruses. After leaving NIH in 1968, he continued his research with respiratory viruses, first as chief of the division of infectious diseases at the University of Colorado department of pediatrics and then, from 1979, as clinical chief of the division of infectious diseases at Children’s Hospital Boston. There in the mid-1980s, he responded to the new HIV/AIDS epidemic by starting and directing the AIDS and Clinical Research Programs while pursuing collaborative projects on HIV/AIDS in the United States, northern Thailand and Africa. Today, McIntosh teaches and continues research on the prevention and treatment of pediatric HIV infections.

His lecture will be a historical, philosophical and personal account of human coronaviruses, a virus family that includes the causes of SARS and the common cold. He will describe their biology, epidemiology and pathogenicity and emphasize the research contributions made by Chanock and his colleagues.

The lecture honors Chanock, who served as LID chief for more than three decades. During an accomplished scientific career, Chanock and collaborators identified and characterized human respiratory syncytial virus (RSV), discovered the four parainfluenza viruses, isolated new strains of rhinovirus and coronavirus and isolated and characterized Mycoplasma pneumoniae. At LID, he and his team developed and brought to FDA licensure an antibody to prevent RSV disease, which can cause serious symptoms in young children.

back to top of page